These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

252 related items for PubMed ID: 19436134

  • 1. Mutant FGF23 prevents the progression of chronic kidney disease but aggravates renal osteodystrophy in uremic rats.
    Kusano K, Saito H, Segawa H, Fukushima N, Miyamoto K.
    J Nutr Sci Vitaminol (Tokyo); 2009 Apr; 55(2):99-105. PubMed ID: 19436134
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Direct inhibition of osteoblastic Wnt pathway by fibroblast growth factor 23 contributes to bone loss in chronic kidney disease.
    Carrillo-López N, Panizo S, Alonso-Montes C, Román-García P, Rodríguez I, Martínez-Salgado C, Dusso AS, Naves M, Cannata-Andía JB.
    Kidney Int; 2016 Jul; 90(1):77-89. PubMed ID: 27165819
    [Abstract] [Full Text] [Related]

  • 6. Inflammation both increases and causes resistance to FGF23 in normal and uremic rats.
    Rodríguez-Ortiz ME, Díaz-Tocados JM, Muñoz-Castañeda JR, Herencia C, Pineda C, Martínez-Moreno JM, Montes de Oca A, López-Baltanás R, Alcalá-Díaz J, Ortiz A, Aguilera-Tejero E, Felsenfeld A, Rodríguez M, Almadén Y.
    Clin Sci (Lond); 2020 Jan 17; 134(1):15-32. PubMed ID: 31860056
    [Abstract] [Full Text] [Related]

  • 7. Longitudinal evaluation of FGF23 changes and mineral metabolism abnormalities in a mouse model of chronic kidney disease.
    Stubbs JR, He N, Idiculla A, Gillihan R, Liu S, David V, Hong Y, Quarles LD.
    J Bone Miner Res; 2012 Jan 17; 27(1):38-46. PubMed ID: 22031097
    [Abstract] [Full Text] [Related]

  • 8. Effects of 1 alpha-hydroxyvitamin D3 on experimental uremic renal osteodystrophy in rats induced by Na-sulfacetylthiazole.
    Okano K, Nakai R, Tomori T, Yoshikawa M.
    Endocrinol Jpn; 1978 Dec 17; 25(6):553-9. PubMed ID: 751801
    [No Abstract] [Full Text] [Related]

  • 9. Fortified phosphorus‑lowering treatment through administration of lanthanum protects against vascular calcification via regulation of FGF23 in chronic kidney disease.
    Jiang J, Li Y, Zheng D, Wang Z, Zhou H, Liu G.
    Int J Mol Med; 2020 Nov 17; 46(5):1783-1793. PubMed ID: 32901861
    [Abstract] [Full Text] [Related]

  • 10. Effect of paricalcitol and cinacalcet on serum phosphate, FGF-23, and bone in rats with chronic kidney disease.
    Finch JL, Tokumoto M, Nakamura H, Yao W, Shahnazari M, Lane N, Slatopolsky E.
    Am J Physiol Renal Physiol; 2010 Jun 17; 298(6):F1315-22. PubMed ID: 20200094
    [Abstract] [Full Text] [Related]

  • 11. The relationship between urinary kidney injury molecule-1 and blood bone metabolism markers in patients with chronic kidney disease
.
    Yin C, Cheng C, Wang J, Zhang L, Purrunsing Y, Yang G, Zeng M, Huang H, Ren W, Ye Y, Ma H, Xing C, Wang N.
    Clin Nephrol; 2020 Feb 17; 93(2):65-76. PubMed ID: 31793871
    [Abstract] [Full Text] [Related]

  • 12. Fibroblast growth factor 23 is upregulated in the kidney in a chronic kidney disease rat model.
    Sugiura H, Matsushita A, Futaya M, Teraoka A, Akiyama KI, Usui N, Nagano N, Nitta K, Tsuchiya K.
    PLoS One; 2018 Feb 17; 13(3):e0191706. PubMed ID: 29518087
    [Abstract] [Full Text] [Related]

  • 13. FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality.
    Shalhoub V, Shatzen EM, Ward SC, Davis J, Stevens J, Bi V, Renshaw L, Hawkins N, Wang W, Chen C, Tsai MM, Cattley RC, Wronski TJ, Xia X, Li X, Henley C, Eschenberg M, Richards WG.
    J Clin Invest; 2012 Jul 17; 122(7):2543-53. PubMed ID: 22728934
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease.
    Carrillo-López N, Panizo S, Alonso-Montes C, Martínez-Arias L, Avello N, Sosa P, Dusso AS, Cannata-Andía JB, Naves-Díaz M.
    Nephrol Dial Transplant; 2019 Jun 01; 34(6):934-941. PubMed ID: 30189026
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Severe hyperparathyroidism with bone abnormalities and metastatic calcification in rats with adenine-induced uraemia.
    Tamagaki K, Yuan Q, Ohkawa H, Imazeki I, Moriguchi Y, Imai N, Sasaki S, Takeda K, Fukagawa M.
    Nephrol Dial Transplant; 2006 Mar 01; 21(3):651-9. PubMed ID: 16311258
    [Abstract] [Full Text] [Related]

  • 20. Role of low protein and low phosphorus diet in the progression of chronic kidney disease in uremic rats.
    Kusano K, Segawa H, Ohnishi R, Fukushima N, Miyamoto K.
    J Nutr Sci Vitaminol (Tokyo); 2008 Jun 01; 54(3):237-43. PubMed ID: 18635911
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.